Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1642 views | HTML 1898 views | ?
Eun Ho Kim1, Mi-Sook Kim2,*, Kyung-Hee Lee3, Jae-Soo Koh4, Won-Gyun Jung1, Chang-Bae Kong3,*
1Division of Heavy Ion Clinical Research, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
2Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
3Department of Orthopaedic Surgery, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
4Department of Pathology, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
*These authors have contributed equally to this work
Mi-Sook Kim, email: [email protected]
Chang-Bae Kong, email: [email protected]
Keywords: zoledronic acid, radiosensitivity, osteosarcoma cells, apoptosis, DNA damage
Received: December 30, 2015 Accepted: September 12, 2016 Published: September 27, 2016
To overcome radioresistance in the treatment of osteosarcoma, a primary malignant tumor of the bone, radiotherapy is generally combined with radiosensitizers. The purpose of this study was to investigate a third-generation bisphosphonate, zoledronic acid (ZOL), as a radiosensitizer for osteosarcoma. We found that exposure of KHOS/NP osteosarcoma cells to 20 μM ZOL decreased the γ-radiation dose needed to kill 90% of cells. This radiosensitizing effect of ZOL was mediated through decreased mitochondrial membrane potential, increased levels of reactive oxygen species, increased DNA damage (as assessed by counting γ-H2AX foci), decreased abundance of proteins involved in DNA repair pathways (ATR, Rad52, and DNA-PKcs), and decreased phosphorylation of PI3K-Akt and MAPK pathway proteins (Raf1, MEK1/2, ERK1/2, and Akt), as compared to γ-irradiation alone. Cells treated with ZOL plus γ-irradiation showed impaired cell migration and invasion and reduced expression of epithelial-mesenchymal transition markers (vimentin, MMP9, and Slug). In Balb/c nude mice, the mean size of orthotopic osteosarcoma tumors 2 weeks post-inoculation was 195 mm3 following γ-irradiation (8 Gy), while it was 150 mm3 after γ-irradiation plus ZOL treatment (0.1 mg/kg twice weekly for 2 weeks). These results provide a rationale for combining ZOL with radiotherapy to treat osteosarcoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.